# Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy

Study · id `cardio:ct-nct07436182` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07436182](<https://clinicaltrials.gov/study/NCT07436182>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07436182

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 176 participants.

## Technical summary

Registry record NCT07436182. Randomized; single masking; primary purpose basic science. Start 2026-03-01 (anticipated); primary completion 2026-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 176 participants (planned count; ClinicalTrials.gov record NCT07436182, source copy `cardio:ctgov-nct07436182-2026-02-27`, retrieved 2026-10-26)
- Planned start: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT07436182, source copy `cardio:ctgov-nct07436182-2026-02-27`, retrieved 2026-10-26)
- Primary completion: 2026-06-01 (anticipated) (ClinicalTrials.gov record NCT07436182, source copy `cardio:ctgov-nct07436182-2026-02-27`, retrieved 2026-10-26)
- Completion: 2026-06-01 (anticipated) (ClinicalTrials.gov record NCT07436182, source copy `cardio:ctgov-nct07436182-2026-02-27`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07436182, source copy `cardio:ctgov-nct07436182-2026-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07436182-2026-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy
- Acronym: MIRROR-DM
- Condition: Mitochondria
- Condition: Metformin
- Intervention (Drug): Imeglimin
- Intervention (Drug): Metformin 1000 mg Oral Tablet
- Lead sponsor: Mansoura University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Mansoura University (`cardio:org-mansoura-university`)

## Provenance

Content hash: aaa6a418c221dd8810d81c0a9ff07c7a94cbd0d4847a03e3df67fd969564c015
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
